GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (FRA:01P) » Definitions » Beneish M-Score

Medpace Holdings (FRA:01P) Beneish M-Score : -2.89 (As of May. 04, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.89 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Medpace Holdings's Beneish M-Score or its related term are showing as below:

FRA:01P' s Beneish M-Score Range Over the Past 10 Years
Min: -3.04   Med: -2.71   Max: -2.09
Current: -2.89

During the past 11 years, the highest Beneish M-Score of Medpace Holdings was -2.09. The lowest was -3.04. And the median was -2.71.


Medpace Holdings Beneish M-Score Historical Data

The historical data trend for Medpace Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings Beneish M-Score Chart

Medpace Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.62 -2.85 -2.59 -2.81 -2.73

Medpace Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.04 -2.73 -2.71 -2.73 -2.89

Competitive Comparison of Medpace Holdings's Beneish M-Score

For the Diagnostics & Research subindustry, Medpace Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Beneish M-Score falls into.



Medpace Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Medpace Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8806+0.528 * 1.0612+0.404 * 0.7998+0.892 * 1.2116+0.115 * 0.8782
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9512+4.679 * -0.109872-0.327 * 0.829
=-2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was €257 Mil.
Revenue was 470.16 + 457.034 + 461.472 + 425.381 = €1,814 Mil.
Gross Profit was 142.731 + 125.451 + 124.802 + 114.745 = €508 Mil.
Total Current Assets was €685 Mil.
Total Assets was €1,652 Mil.
Property, Plant and Equipment(Net PPE) was €237 Mil.
Depreciation, Depletion and Amortization(DDA) was €25 Mil.
Selling, General, & Admin. Expense(SGA) was €155 Mil.
Total Current Liabilities was €880 Mil.
Long-Term Debt & Capital Lease Obligation was €125 Mil.
Net Income was 94.384 + 71.799 + 66.105 + 56.366 = €289 Mil.
Non Operating Income was 4.226 + 1.415 + -1.501 + -1.184 = €3 Mil.
Cash Flow from Operations was 140.463 + 143.414 + 107.179 + 76.164 = €467 Mil.
Total Receivables was €241 Mil.
Revenue was 405.425 + 372.029 + 387.581 + 332.242 = €1,497 Mil.
Gross Profit was 121.597 + 109.25 + 120.224 + 93.65 = €445 Mil.
Total Current Assets was €343 Mil.
Total Assets was €1,304 Mil.
Property, Plant and Equipment(Net PPE) was €240 Mil.
Depreciation, Depletion and Amortization(DDA) was €22 Mil.
Selling, General, & Admin. Expense(SGA) was €134 Mil.
Total Current Liabilities was €824 Mil.
Long-Term Debt & Capital Lease Obligation was €133 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(256.833 / 1814.047) / (240.735 / 1497.277)
=0.14158 / 0.160782
=0.8806

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(444.721 / 1497.277) / (507.729 / 1814.047)
=0.29702 / 0.279887
=1.0612

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (685.31 + 236.811) / 1652.126) / (1 - (343.359 + 240.098) / 1303.605)
=0.441858 / 0.552428
=0.7998

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1814.047 / 1497.277
=1.2116

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(22.227 / (22.227 + 240.098)) / (25.289 / (25.289 + 236.811))
=0.084731 / 0.096486
=0.8782

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(154.708 / 1814.047) / (134.241 / 1497.277)
=0.085283 / 0.089657
=0.9512

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((125.264 + 880.113) / 1652.126) / ((133.272 + 823.684) / 1303.605)
=0.608535 / 0.734084
=0.829

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(288.654 - 2.956 - 467.22) / 1652.126
=-0.109872

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Medpace Holdings has a M-score of -2.91 suggests that the company is unlikely to be a manipulator.


Medpace Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Medpace Holdings (FRA:01P) Business Description

Traded in Other Exchanges
Address
5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.

Medpace Holdings (FRA:01P) Headlines

No Headlines